



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## C646

|                    |                                                                                                    |
|--------------------|----------------------------------------------------------------------------------------------------|
| Cat. No.:          | HY-13823                                                                                           |
| CAS No.:           | 328968-36-1                                                                                        |
| Molecular Formula: | C <sub>24</sub> H <sub>19</sub> N <sub>3</sub> O <sub>6</sub>                                      |
| Molecular Weight:  | 445.42                                                                                             |
| Target:            | Histone Acetyltransferase; Autophagy; Epigenetic Reader Domain; Apoptosis                          |
| Pathway:           | Epigenetics; Autophagy; Apoptosis                                                                  |
| Storage:           | Powder    -20°C    3 years<br>4°C    2 years<br>In solvent   -80°C    6 months<br>-20°C    1 month |



### SOLVENT & SOLUBILITY

|                                                                               |                                                                                                                                                              |                                                       |      |           |            |            |
|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------|-----------|------------|------------|
| In Vitro                                                                      | DMSO : 13.89 mg/mL (31.18 mM; ultrasonic and warming and heat to 60°C)                                                                                       |                                                       |      |           |            |            |
|                                                                               | Preparing Stock Solutions                                                                                                                                    | <div><div>Solvent</div><div>Concentration</div></div> | Mass | 1 mg      | 5 mg       | 10 mg      |
|                                                                               |                                                                                                                                                              | 1 mM                                                  |      | 2.2451 mL | 11.2254 mL | 22.4507 mL |
|                                                                               |                                                                                                                                                              | 5 mM                                                  |      | 0.4490 mL | 2.2451 mL  | 4.4901 mL  |
|                                                                               |                                                                                                                                                              | 10 mM                                                 |      | 0.2245 mL | 1.1225 mL  | 2.2451 mL  |
| Please refer to the solubility information to select the appropriate solvent. |                                                                                                                                                              |                                                       |      |           |            |            |
| In Vivo                                                                       | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline<br>Solubility: 1.67 mg/mL (3.75 mM); Suspended solution; Need ultrasonic |                                                       |      |           |            |            |
|                                                                               | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)<br>Solubility: 1.67 mg/mL (3.75 mM); Suspended solution; Need ultrasonic            |                                                       |      |           |            |            |

### BIOLOGICAL ACTIVITY

|                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description               | C646 is a selective and competitive histone acetyltransferase p300 inhibitor with K <sub>i</sub> of 400 nM, and is less potent for other acetyltransferases <sup>[1]</sup> .                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IC <sub>50</sub> & Target | CBP/p300                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| In Vitro                  | C646 is a linear competitive inhibitor of p300 versus acetyl-CoA with a K <sub>i</sub> of 400 nM. C646 shows a noncompetitive pattern of p300 inhibition versus the H4-15 peptide substrate. C646 treatment reduces histone H3 and H4 acetylation levels and abrogates TSA-induced acetylation in cells. C646 has a more potent effect on cell growth than Lys-CoA-Tat does <sup>[1]</sup> .<br>C646 enhances mitotic catastrophe after IR and suppresses phosphorylation of CHK1 after IR in A549 cells <sup>[2]</sup> . C646 attenuates the increased acetylation of GATA1 and the increased transcriptional activity of GATA1 induced by EDAG <sup>[3]</sup> . |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Suppression of P300 by c646 (intraperitoneally injected, 30 nmol/g/d for 2 weeks) dramatically reduces the level of blood glucose in db/db mice<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

|                 |                                                                                                         |
|-----------------|---------------------------------------------------------------------------------------------------------|
| Animal Model:   | Fourteen-week-old male db/db mice and normal m/m mice <sup>[4]</sup>                                    |
| Dosage:         | 30 nmol/g                                                                                               |
| Administration: | Intraperitoneally injected; daily; 2 weeks                                                              |
| Result:         | The db/db mice showed greater body masses and higher levels of fasting blood glucose than the m/m mice. |

## CUSTOMER VALIDATION

- Cell Res. 2023 Jul 13.
- Immunity. 2024 Feb 13;57(2):364-378.e9.
- Nat Microbiol. 2021 Jul;6(7):932-945.
- Adv Funct Mater. 2023 Dec 21.
- Nucleic Acids Res. 2019 Mar 18;47(5):2455-2471.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Bowers EM, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010 May 28;17(5):471-82.
- [2]. Oike T, et al. C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe. Radiother Oncol. 2014 May;111(2):222-7.
- [3]. Zheng WW, et al. EDAG positively regulates erythroid differentiation and modifies GATA1 acetylation through recruiting p300. Stem Cells. 2014 Aug;32(8):2278-89.
- [4]. Zhen Fan, et al. Type 2 diabetes-induced overactivation of P300 contributes to skeletal muscle atrophy by inhibiting autophagic flux. Life Sci. 2020 Aug 10;258:118243.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA